Analytical confirmation of synthetic cannabinoids in a cohort of 179 presentations with acute recreational drug toxicity to an Emergency Department in London, UK in the first half of 2015

References

• European Monitoring Centre for Drugs and Drug Addiction [Internet]. European Drug Report (Trends and Developments) 2015. Luxembourg: Publications Office of the European Union; 2015 [cited 2015 Nov 15]. Available from: http://www.emcdda.europa.eu/edr2015
   Google Scholar
• United Nations Office on Drugs and Crime [Internet]. Global SMART Update Volume 13, March 2015. Special Segment Synthetic cannabinoids: Key facts about the largest and most dynamic group of NPS. [cited 2015 Dec 10]. Available from: https://www.unodc.org/documents/scientific/Global_SMART_Update_13_web.pdf
   Google Scholar
• United Nations. Economic and Social Council. Official Records, 2015 [Internet]. Supplement No. 8. Commission on Narcotic Drugs. Report on the fifty-eighth session (2014 Dec 5 and 2015 March 9–17) E/2015/28. E/CN.7/2015/15. [cited 2016 Mar 10] Available from: https://www.unodc.org/documents/commissions/CND/CND_Sessions/CND_58/E2015_28_ADVANCE_UNEDITED_VERSION.pdf
   Google Scholar
• Harris CR, Brown A. Synthetic cannabinoid intoxication: a case series and review. J Emerg Med. 2013;44:360–366.
   PubMed Web of Science ®Google Scholar
• Brandt SD, Freeman S, Sumnall HR, et al. Analysis of NRG ‘legal highs’ in the UK: identification and formation of novel cathinones. Drug Test Anal. 2011;3:569–575.
   PubMed Web of Science ®Google Scholar
• Lovett C, Wood DM, Dargan PI. Pharmacology and toxicology of the synthetic cannabinoid receptor agonists. Réanimation. 2015;24:527–541.
   Google Scholar
• Tait RJ, Caldicott D, Mountain D, et al. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol. 2016;54:1–13.
   PubMed Web of Science ®Google Scholar
• Forrester MB, Kleinschmidt K, Schwarz E, et al. Synthetic cannabinoid exposures reported to Texas poison centers. J Addict Dis. 2011;30:351–358.
   PubMed Web of Science ®Google Scholar
• Hoyte CO, Jacob J, Monte AA, et al. A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010. Ann Emerg Med. 2012;60:435–438.
   PubMed Web of Science ®Google Scholar
• Davies S, Wood DM, Smith G, et al. Purchasing “legal highs on the Internet-is there consistency in what you get?” QJM. 2010;103:489–493.
   PubMed Web of Science ®Google Scholar
• Wood DM, Stribley V, Dargan PI, et al. Variability in the 3,4-methylenedioxymethamphetamine content of ‘ecstasy’ tablets in the UK. Emerg Med J. 2011;28:764–765.
   PubMed Web of Science ®Google Scholar
• Ramsey J, Dargan PI, Smyllie M, et al. Buying ‘legal’ recreational drugs does not mean that you are not breaking the law. QJM. 2010;103:777–783.
   PubMed Web of Science ®Google Scholar
• Hudson S, Ramsey J, King L, et al. Use of high-resolution accurate mass spectrometry to detect reported and previously unreported cannabinomimetics in ‘herbal high’ products. J Anal Toxicol. 2009;34:252–260.
   Web of Science ®Google Scholar
• Frinculescu A, Lyall CL, Ramsey J, et al. Variation in commercial smoking mixtures containing third-generation synthetic cannabinoids. Drug Test Analysis. 2017;9:327–333.
   PubMed Web of Science ®Google Scholar
• Winstock AR, Barratt MJ. The 12-month prevalence and nature of adverse experiences resulting in emergency medical presentations associated with the use of synthetic cannabinoid products. Hum Psychopharmacol Clin Exp. 2013;28:390–393.
   PubMed Web of Science ®Google Scholar
• Winstock AR, Lynskey M, Borschmann R, et al. Risk of emergency medical treatment following consumption of cannabis or synthetic cannabinoids in a large global sample. J Psychopharmacol. 2015;29:698–703.
   PubMed Web of Science ®Google Scholar
• Zaurova M, Hoffman RS, Vlahov D, et al. Clinical effects of synthetic cannabinoid receptor agonists compared with marijuana in emergency department patients with acute drug overdose. J Med Toxicol. 2016;12:335–340.
   PubMed Web of Science ®Google Scholar
• Greene SL, Wood DM, Gawarammana IB, et al. Improvement in the management of acutely poisoned patients using an electronic database, prospective audit and targeted educational intervention. Postgrad Med J. 2008;84:603–608.
   PubMed Web of Science ®Google Scholar
• Wood DM, Heyerdahl F, Yates CB, et al. The European Drug Emergencies Network (Euro-DEN). Clin Toxicol. 2014;52:239–241.
   PubMed Web of Science ®Google Scholar
• Rosano TG, Wood M, Ihenetu K, et al. Drug screening in medical examiner casework by high-resolution mass spectrometry (UPLC–MSE-TOF). J Anal Toxicol. 2013;37:580–593.
   PubMed Web of Science ®Google Scholar
• Sadones N, Van Bever E, Archer JRH, et al. Microwave-assisted on-spot derivatization for gas chromatography-mass spectrometry based determination of polar low molecular weight compounds in dried blood spots. J Chromatogr A. 2016;1465:175–183.
   PubMed Web of Science ®Google Scholar
• Home Office [Internet]. Annual Report on the Home Office Forensic Early Warning System (FEWS). A system to identify New Psychoactive Substances (NPS) in the UK. United Kingdom; 2015 [cited 2016 Mar 12]. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/461333/1280_EL_FEWS_Annual_Report_2015_WEB.pdf
   Google Scholar
• Advisory Council on the Misuse of Drugs [Internet]. ‘Third Generation’ Synthetic Cannabinoids. United Kingdom; 2014 [cited 2016 Apr 30]. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/380161/CannabinoidsReport.pdf
   Google Scholar
• Trecki J, Gerona RR, Schwartz MD. Synthetic cannabinoid-related illnesses and deaths. N Engl J Med. 2015;373:103–107.
   PubMed Web of Science ®Google Scholar
• Tyndall JA, Gerona R, De Portu G, et al. An outbreak of acute delirium from exposure to the synthetic cannabinoid AB-CHMINACA. Clin Toxicol. 2015;53:950–956.
   PubMed Web of Science ®Google Scholar
• Hermanns-Clausen M, Muller D, Kithinji J, et al. Acute side effects after consumption of the novel synthetic cannabinoids AB-CHMINACA and MDMB-CHMICA. 36th International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) 24–27 May, 2016, Madrid, Spain. Clin Toxicol. 2016;54:344–519 (Abstract 17).
   Web of Science ®Google Scholar
• Haden M, Dargan PI, Archer JRH, et al. MDMB-CHMICA: availability, patterns of use and toxicity associated with this novel psychoactive substance. Subst Use Misuse. 2017;52:223–232.
   PubMed Web of Science ®Google Scholar
• Westin AA, Frost J, Brede WR, et al. Sudden cardiac death following use of the synthetic cannabinoid MDMB-CHMICA. J Anal Toxicol. 2016;40:86–87.
   PubMed Web of Science ®Google Scholar
• Adamowicz P. Fatal intoxication with synthetic cannabinoid MDMB-CHMICA. Forensic Sci Int. 2016;261:e5–10.
   PubMed Web of Science ®Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction [Internet]. EMCDDA–Europol Joint Report on a new psychoactive substance: methyl 2-[[1-(cyclohexylmethyl)indole-3-carbonyl]amino]-3,3-dimethylbutanoate (MDMB-CHMICA), Joint Reports. Luxembourg: Publications Office of the European Union; 2016 [cited 2016 May 23]. Available from: http://www.emcdda.europa.eu/system/files/publications/2873/2016.4528_WEB.pdf
   Google Scholar
• Hill SL, Najafi J, Dunn M, et al. Clinical toxicity following analytically confirmed use of the synthetic cannabinoids MDMBCHMICA. A report from the Identification Of Novel psychoActive substances (IONA) study. Clin Toxicol. 2016;54:638–643.
   PubMed Web of Science ®Google Scholar
• Angerer V, Franz F, Schwarze B, et al. Reply to 'Sudden cardiac death following use of the synthetic cannabinoid MDMB-CHMICA'. J Anal Toxicol. 2016;40:240–242.
   PubMed Web of Science ®Google Scholar
• Schep LJ, Slaughter RJ, Hudson S, et al. Delayed seizure-like activity following analytically confirmed use of previously unreported synthetic cannabinoid analogues. Hum Exp Toxicol. 2015;34:557–560.
   PubMed Web of Science ®Google Scholar
• Gugelmann H, Gerona R, Li C, et al. 'Crazy Monkey' poisons man and dog: Human and canine seizures due to PB-22, a novel synthetic cannabinoid. Clin Toxicol. 2014;52:635–638.
   PubMed Web of Science ®Google Scholar
• Hussain F, Al-musawi H, Al-khateeb E, et al. Ischemic cerebrovasular accident, uncontrolled seizures and acute myocardial infarction associated with synthetic marijuana abuse. Am J Ind Med. 2014;2:138–143.
   Google Scholar
• Hermanns-Clausen M, Kneisel S, Szabo B, et al. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction. 2013;108:534–544.
   PubMed Web of Science ®Google Scholar
• Behonick G, Shanks KG, Firchau DJ, et al. Four postmortem case reports with quantitative detection of the synthetic cannabinoid, 5F-PB-22. J Anal Toxicol. 2014;38:559–562.
   PubMed Web of Science ®Google Scholar
• Karinen R, Tuv SS, Øiestad EL, et al. Concentrations of APINACA, 5F-APINACA, UR-144 and its degradant product in blood samples from six impaired drivers compared to previous reported concentrations of other synthetic cannabinoids. Forensic Sci Int. 2015;246:98–103.
   PubMed Web of Science ®Google Scholar
• Gunja N, Kuligowski K, Paul PG, et al. Acute agitation and chest pain from 5-fluoro-AKB48: a novel synthetic cannabinoid. (abstract 162). XXXIV International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) 27?30 May 2014, Brussels, Belgium. Clin Toxicol. 2014;52:295–443.
   Web of Science ®Google Scholar